The effectiveness of interventions to treat severe acute malnutrition in young children: a systematic review

J Picot,1 D Hartwell,1 P Harris,1 D Mendes,1 AJ Clegg1* and A Takeda1,2

1Southampton Health Technology Assessments Centre, University of Southampton, Southampton, UK
2Centre for Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, London, UK

*Corresponding author

Executive summary

Health Technology Assessment 2012; Vol. 16: No. 19
DOI: 10.3310/hta16190
Executive summary

Background

Undernutrition (referred to here as malnutrition) makes a major contribution to the global disease burden, accounting for more than one-third of child deaths worldwide. Acute malnutrition arises as a consequence of a sudden/sharp period of food shortage and is associated with loss of body fat and wasting of skeletal muscle. Malnutrition can be classified as mild, moderate or severe based on anthropometry (measurement of the size, weight and proportions of the human body), biochemistry and clinical assessment. The focus of this report is on severe acute malnutrition (SAM). A defining feature of SAM is severe wasting. In developing countries, some 19 million children < 5 years old are severely wasted. In 2004, approximately 310,000 deaths among these children in Africa, Asia and Latin America were attributed to severe wasting. Forms of SAM include kwashiorkor, marasmus and marasmic kwashiorkor.

Standard and accepted methods for defining and/or classifying SAM in children < 5 years of age have been established by organisations such as the World Health Organization (WHO) and the United Nations, although a variety of definitions exist, differing in the specific criteria and thresholds used. In addition, differences in treatment practices have been found to be a key factor in the large variation in mortality rates of severely malnourished children during treatment. To try and improve identification and treatment of SAM, WHO introduced guidance in 1999 that provided a 10-step ordered approach through three treatment phases. In the first phase of initial treatment, the focus is on stabilising the child's condition. The second phase of rehabilitation involves increasing the energy content and volume of the feeds to recover lost weight. The third phase begins after discharge and focuses on following up the child and his or her family at home, and providing support in order to prevent relapse and ensure the continued development of the child. However, implementation of this guidance in the 20 countries that are home to 80% of the world's undernourished children is variable. As a result of this, and many other factors, mortality from SAM remains unacceptably high.

Objectives

The objective of this report was to systematically review the evidence assessing interventions, programmes and/or guidelines to treat infants and children aged < 5 years of age who have SAM. The effects that factors such as the setting (e.g. hospital, community, emergency) or different comorbidities [e.g. human immunodeficiency virus (HIV) infection] have on their effectiveness have also been examined.

Methods

Data sources

A sensitive search strategy was designed and applied to eight electronic bibliographic databases, including MEDLINE (1950 onwards), EMBASE (1980 onwards) and The Cochrane Library (from inception to November/December 2010). Bibliographies of included articles and grey literature sources were searched, and the project expert advisory group was contacted to identify additional published and unpublished references.
**Study selection**

Titles and abstracts were screened independently by two reviewers. Inclusion criteria were defined a priori and applied to the full text of retrieved papers by one reviewer and checked independently by a second. The inclusion criteria were as follows.

- **Study design**: randomised controlled trials (RCTs), controlled clinical trials (CCTs), cohort studies (with control group) and case–control studies were eligible for inclusion. Evidence from studies with the most rigorous designs was prioritised based on the hierarchy evidence. Studies without a comparator group or those with a comparator group that did not have SAM (e.g. healthy individuals) were excluded.
- **Interventions**: any intervention for treating SAM (either an entire treatment plan or any individual treatment step).
- **Comparators**: any alternative treatment strategy (including no intervention and placebo).
- **Population**: infants and children <5 years of age with SAM. The set of criteria for the definition/classification of SAM were agreed following consultation with the expert advisory group and included WHO's and the United Nations Children's Fund's reference standards, the Wellcome working party's, Gómez and colleagues' and the Indian Academy of Paediatrics' classifications, mid-upper arm circumference <115 mm, clinical oedema and diagnoses of marasmus, kwashiorkor or marasmic kwashiorkor.
- **Outcomes**: studies were included providing they reported on measures of mortality or weight change.

**Delphi process and map of the evidence base**

A Delphi process was used in order to gain an understanding of the priority order of the research questions relating to the WHO 10-step plan. A ‘map’ of the evidence base was created, as each study was mapped to the prioritised research question(s) it primarily addressed by one reviewer. The decision was checked by a second reviewer. After the available evidence had been mapped, the final decision on how many questions would be addressed by the systematic review was taken, based on the extent of the evidence and the resources available for the research.

**Data extraction and assessment of validity**

Data were extracted and study quality was assessed by one reviewer and checked by a second. Discrepancies were resolved by discussion, with involvement of a third reviewer when necessary. Included studies that mapped to questions that could not be assessed in the systematic review, and studies that did not map to any question were not data extracted or quality assessed.

**Data synthesis**

Studies were synthesised through a narrative review with tabulation of results of included studies.

**Results**

**Quantity and quality of studies**

A total of 8954 records were identified. Seventy-four references describing 68 studies met the general review inclusion criteria. The available evidence mapped against 9 of the 15 questions prioritised in the Delphi process. For one other question, very limited evidence was available in two studies. No evidence was found to inform the remaining five questions. Project resources were available to review the evidence for the first six questions for which any evidence was available. Only the best available evidence was reviewed and, for all but one question, this meant that only RCTs and CCTs were included.
**Summary of benefits and risks**

**What methods are effective for treating severe acute malnutrition among infants <6 months old?**

No research focused on treating SAM in infants <6 months old. Two cohort studies included this age group within their study populations. However, baseline data were not reported separately for this subgroup and only a very limited quantity of separate outcome information was provided. No formal quality assessment was undertaken.

**Which form of intravenous fluid administration is most effective for treating shock?**

One RCT of moderate methodological quality compared the efficacy of three fluid resuscitation solutions for treating hypovolaemic shock in children with SAM. The principal comparison was between Ringer's lactate isotonic fluid (RL) and the WHO hypotonic fluid solution [half-strength Darrow's in 5% dextrose (HSD/5D)] because few participants received 4.5% human albumin solution (HAS). Hypotonic HSD/5D was given according to the WHO recommendation, whereas similar volumes and rates of the isotonic RL and HAS solutions were administered to a different schedule. Other aspects of management in all groups followed WHO guidelines. The study found that neither the standard WHO hypotonic HSD/5D nor the RL isotonic resuscitation fluids were effective in reducing mortality or adequately treating shock after 48 hours of treatment. However, it should be noted that the study was prematurely terminated because of high overall mortality and inadequate correction of shock in all study arms.

**What are the best treatments for children with severe acute malnutrition who have diarrhoea?**

Five RCTs of strong or moderate methodological quality focused on children with acute diarrhoea and three RCTs of strong or weak methodological quality focused on children with persistent diarrhoea.

**Acute diarrhoea**

Four of the five RCTs compared oral rehydration solutions (ORSs). The fifth RCT investigated standard WHO-ORS alongside a zinc-containing syrup compared with WHO-ORS and placebo. Children with acute diarrhoea benefited from the use of hypo-osmolar oral rehydration solution compared with the standard WHO-ORS on measures of frequency, duration and recovery from diarrhoea and consumption of ORS. In contrast, weight gain was significantly higher in those receiving WHO-ORS (one study). WHO-ORS was not significantly different from rehydration solution for malnutrition (ReSoMaL) for mortality or adequacy of hydration, although ReSoMal may pose safety concerns. A rice-based ORS was more beneficial at 72 hours in promoting weight gain and reducing diarrhoeal output than glucose-based ORSs, whereas the provision of zinc and a WHO-ORS had a favourable impact on diarrhoeal outcomes and reduced the need for ORS.

**Persistent diarrhoea**

These studies compared different diets and had conflicting findings. Although a comparison in one study of an elemental diet with a skimmed milk and soy-based diet showed significant benefits on anthropometric measures for the elemental diet, two other studies either showed no difference between an elemental diet, soy-based diet and a chicken-based diet on mortality, weight gain, frequency of diarrhoea and recovery, or showed a significant benefit on anthropometric measures and ORS consumption from a soy-based diet compared with a khitchri and yoghurt-based diet.
What methods are effective in treating infection?
Two studies of moderate methodological quality (one RCT and one retrospective cohort analysis) investigated the use of antibiotic therapy in children with SAM, but neither focused on treating diagnosed infection. The retrospective observational evidence indicates that the systematic addition of a broad-spectrum antibiotic to home-based treatment with ready-to-use therapeutic food has a statistically significant detrimental effect on the initial recovery (4 weeks) of children with SAM, although later (12 weeks) the proportion recovered was similar and no effect was shown on mortality. The RCT comparing administration of intramuscular ceftriaxone with orally administered amoxicillin showed no difference in effects on outcomes, apart from ceftriaxone being associated with fewer adverse events.

What is the clinical effectiveness of interventions in different settings (e.g. hospital, community, emergency)?
Four included studies, of moderate or weak methodological quality, investigated the clinical effectiveness of SAM treatment in different settings. There were numerous differences between these trials and, although the inpatient hospital setting was included in all trials, the type of inpatient care provided varied. It appears that children receiving inpatient care do as well as, if not better than, those receiving care in the ambulatory or home setting on anthropometric measures and response time to treatment. Longer-term follow-up showed limited differences between the different settings.

Which methods for correcting micronutrient deficiencies are effective?
Thirteen studies evaluated the effect of supplements to correct micronutrient deficiencies. Of these, 10 RCTs focused on the provision of zinc supplements, whereas the remaining three investigated potassium, nicotinic acid or nucleotides (NTs). Although the methodological quality of studies varied, > 80% were either moderate (n = 3) or weak (n = 8).

Zinc
The provision of zinc varied in a number of aspects (e.g. when supplementation began, dose or duration of supplementation). In seven trials, the comparator was no zinc/placebo, whereas three compared different doses/duration of zinc. Although studies assessing the effects of supplementary zinc were heterogeneous, those considered of a higher methodological quality showed no significant benefit from the addition of zinc supplementation. If there is a benefit to be obtained from zinc supplementation, the included evidence is insufficient to determine which dose of zinc might represent the optimal balance between maximising benefits and minimising any harms.

Other supplements
Evidence on other micronutrients was limited, with significant benefits from the addition of potassium (i.e. reducing late deaths, sepsis, skin ulcers) and nicotinic acid (i.e. weight gain), but no benefit from the addition of NTs.

Conclusions
Evidence for the first six prioritised questions for which any evidence was available was often lacking or not always conclusive. In addition, the diversity of the interventions made
Executive summary: The effectiveness of interventions to treat SAM in young children

comparisons between studies difficult. No good-quality evidence or adequately reported studies assessed treatments for SAM in infants < 6 months old and neither of the studies evaluating antibiotic therapy focused on treating diagnosed infection. Neither of the resuscitation fluids was effective in treating children with hypovolaemic shock, and no clear benefit was evident from the addition of zinc supplementation in correcting micronutrient deficiencies. Inpatient care was found to be beneficial, or at least comparable, to the ambulatory or home setting for treating children with SAM, whereas trials of children with both acute and persistent diarrhoea found conflicting results.

Recommendations for further research

- Treatments for SAM in infants < 6 months old was one of the highest ranked questions in the Delphi study and, therefore, more research is needed to fill this gap in the evidence base.
- The high priority given to the question of intravenous (i.v.) fluid administration for treating shock, coupled with the potential to significantly improve survival, indicates that further prospective RCTs of alternative i.v. resuscitation regimens for shock are needed. Any RCT should be informed by an initial pilot study and should include measures of cardiac dysfunction and haemodynamic response to fluid expansion.
- More research in treating diagnosed infections in children with SAM is needed because this topic was also ranked highly, and yet little research was found that met the inclusion criteria of the review.
- Additional research could be conducted on many other aspects of the management of SAM in children < 5 years of age, including areas which were also prioritised in the Delphi study but for which little or no research was identified, e.g. use of multivitamin supplements, optimum dose of vitamin A, management strategies for children with HIV infection, tuberculosis or other comorbidities.
- Future trials should include children identified using the current WHO criteria and ideally should involve more than one centre to generate results with better generalisability to other locations and to aid comparison between different trials.

Funding

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.

Publication

How to obtain copies of this and other HTA programme reports

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).

Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue.

How to order:
– fax (with credit card details)
– post (with credit card details or cheque)
– phone during office hours (credit card only).

Additionally the HTA website allows you to either print out your order or download a blank order form.

Contact details are as follows:
Synergie UK (HTA Department) Email: orders@hta.ac.uk
Digital House, The Loddon Centre Tel: 0845 812 4000 – ask for ‘HTA Payment Services’
Wade Road (out-of-hours answer-phone service)
Basingstoke Fax: 0845 812 4001 – put ‘HTA Order’ on the fax header
Hants RG24 8QW

Payment methods

Paying by cheque
If you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.

Paying by credit card
You can order using your credit card by phone, fax or post.

Subscriptions

NHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40–50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.

How do I get a copy of HTA on DVD?

Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.

The website also provides information about the HTA programme and lists the membership of the various committees.
The Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the ‘National Knowledge Service’.

The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects.

First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, from the public and consumer groups and from professional bodies such as royal colleges and NHS trusts. These suggestions are carefully prioritised by panels of independent experts (including NHS service users). The HTA programme then commissions the research by competitive tender.

Second, the HTA programme provides grants for clinical trials for researchers who identify research questions. These are assessed for importance to patients and the NHS, and scientific rigour.

Third, through its Technology Assessment Report (TAR) call-off contract, the HTA programme commissions bespoke reports, principally for NICE, but also for other policy-makers. TARs bring together evidence on the value of specific technologies.

Some HTA research projects, including TARs, may take only months, others need several years. They can cost from as little as £40,000 to over £1 million, and may involve synthesising existing evidence, undertaking a trial, or other research collecting new data to answer a research problem.

The final reports from HTA projects are peer reviewed by a number of independent expert referees before publication in the widely read journal series Health Technology Assessment.